Clinical Scorecard: CACUL1 Enhances Tumor Cell Growth and Immune Suppression by Macrophages, Driving Progression of Hepatocellular Carcinoma

At a Glance

Key Highlights

• CACUL1 overexpression correlates with poor prognosis in HCC.
• Knockout of CACUL1 inhibits HCC cell proliferation and migration.
• CACUL1 promotes M2 macrophage polarization.
• Transcriptomic analysis reveals PI3K/AKT pathway enrichment.
• CACUL1 is a potential prognostic biomarker and therapeutic target.

Guideline-Based Recommendations

Diagnosis

• Use immunohistochemistry to validate CACUL1 expression in HCC.

Management

• Consider targeting CACUL1 in therapeutic strategies for HCC.

Monitoring & Follow-up

• Monitor CACUL1 levels as a prognostic indicator in HCC patients.

Risks

• CACUL1 overexpression is associated with advanced clinicopathological features.

Patient & Prescribing Data

Patients diagnosed with hepatocellular carcinoma.

CACUL1 may serve as a therapeutic target to inhibit tumor growth and immune suppression.

Clinical Best Practices

• Incorporate CACUL1 expression analysis in the evaluation of HCC.
• Utilize CRISPR-mediated knockout studies to explore therapeutic avenues.

Related Resources & Content

• UCSC Xena
• The Cancer Genome Atlas (TCGA)
• Gene Expression Omnibus (GEO)